ERBB2 and breast carcinoma: Taken together, these findings provide compelling preclinical evidence that TRZ−NP offers a mechanistically enhanced and better-tolerated approach to HER2+ breast cancer therapy compared to either the free drugs or the non-targeted dual-drug nanoparticle systems.